Scientists study yearly HIV prevention injection possibility
Scientists are conducting clinical trials to determine if the HIV prevention drug Lenacapavir can be effective as a once-yearly injection. While the current twice-yearly version shows 99 percent effectiveness, researchers hope a single annual dose will improve patient adherence and simplify treatment protocols.
Why it matters
A once-yearly HIV prevention injection could significantly reduce infection rates by overcoming the challenges of frequent dosing and improving long-term public health outcomes.
Health , NEWS Leave a comment
The article reports on medical research and public health logistics in a factual, neutral manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in